Roots Analysis has just released the 2nd edition of their study on 'Cell and Gene Therapy CROs Market, 2021-2030'.
The development of cell and gene therapies is not only complex and challenging, but also subject to heavy regulatory scrutiny. Outsourcing is, therefore, a preferred operational model in this field, with innovator companies relying heavily on specialty contract service providers to handle various aspects of their product development and manufacturing operations. Contract research organizations (CROs) that claim to have the necessary capabilities to facilitate cell and gene therapy-related R&D, usually have extensive experience and are well-aware of the nuances of ATMP design and development. Given the rising trend of outsourcing in the healthcare industry and the ongoing efforts of service providers to further improve/expand their respective offerings, they believe the cell and gene therapy CRO market is likely to evolve at a steady pace, till 2030.
